ALIM stock forecast
Our latest prediction for Alimera Sciences, Inc.'s stock price was made on the Dec. 10, 2019 when the stock price was at 9.35$.
In the short term (2weeks), ALIM's stock price should underperform the market by -7.79%. During that period the price should oscillate between -13.74% and +15.07%.
In the medium term (3months), ALIM's stock price should underperform the market by -17.09%. During that period the price should oscillate between -34.91% and +24.09%.Get email alerts
About Alimera Sciences, Inc.
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.
At the moment the company generates 52M USD in revenues.
On its last earning announcement, the company reported a loss of -2.40$ per share.
The book value per share is -0.90$
Three months stock forecastDec. 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|